To validate the co-existence of different B cells in the microenvironment of NSCLC and determine the clinical relevance of each subtype of B cells, we performed co-staining of CD79A and CD20 in the primary NSCLC tissues by immunohistochemistry and immunofluorescence. The gene discussed is CD79A; the disease is non-small cell lung carcinoma.